Compare Stocks: AGIO, SYRE, ALKS, and RYTM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$33.60	$35.26	$22.24 ▼ $46.00	$2.01B	0.6	797,477 shs	750,165 shs
ALKS Alkermes	$45.97	$49.82	$26.40 ▼ $55.67	$7.71B	0.31	1.21 million shs	1.28 million shs
RYTM Rhythm Pharmaceuticals	$104.71	$108.65	$74.50 ▼ $122.20	$7.18B	1.97	438,820 shs	573,720 shs
SYRE Spyre Therapeutics	$90.60	$98.15	$14.51 ▼ $110.18	$7.97B	2.99	1.12 million shs	886,052 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	0.00%	+1.51%	+0.12%	+5.59%	-8.65%
ALKS Alkermes	0.00%	-0.28%	-6.30%	+3.63%	+70.45%
RYTM Rhythm Pharmaceuticals	0.00%	+1.92%	-9.33%	+16.73%	+8.82%
SYRE Spyre Therapeutics	0.00%	+1.82%	-12.57%	+8.40%	+478.91%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$33.60	$35.26	$22.24 ▼ $46.00	$2.01B	0.6	797,477 shs	750,165 shs
ALKS Alkermes	$45.97	$49.82	$26.40 ▼ $55.67	$7.71B	0.31	1.21 million shs	1.28 million shs
RYTM Rhythm Pharmaceuticals	$104.71	$108.65	$74.50 ▼ $122.20	$7.18B	1.97	438,820 shs	573,720 shs
SYRE Spyre Therapeutics	$90.60	$98.15	$14.51 ▼ $110.18	$7.97B	2.99	1.12 million shs	886,052 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	0.00%	+1.51%	+0.12%	+5.59%	-8.65%
ALKS Alkermes	0.00%	-0.28%	-6.30%	+3.63%	+70.45%
RYTM Rhythm Pharmaceuticals	0.00%	+1.92%	-9.33%	+16.73%	+8.82%
SYRE Spyre Therapeutics	0.00%	+1.82%	-12.57%	+8.40%	+478.91%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGIO Agios Pharmaceuticals	2.55	Moderate Buy	$41.25	22.77% Upside
ALKS Alkermes	2.72	Moderate Buy	$54.56	18.69% Upside
RYTM Rhythm Pharmaceuticals	2.74	Moderate Buy	$141.12	34.77% Upside
SYRE Spyre Therapeutics	2.87	Moderate Buy	$109.69	21.07% Upside

Current Analyst Ratings Breakdown

Latest AGIO, SYRE, ALKS, and RYTM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/9/2026	SYRE Spyre Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$123.00
9/8/2026	SYRE Spyre Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$121.00
9/1/2026	SYRE Spyre Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/28/2026	RYTM Rhythm Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold	$120.00
8/26/2026	SYRE Spyre Therapeutics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$135.00 ➝ $127.00
8/26/2026	SYRE Spyre Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$130.00 ➝ $123.00
8/26/2026	SYRE Spyre Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$132.00 ➝ $121.00
8/24/2026	AGIO Agios Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/11/2026	SYRE Spyre Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$112.00 ➝ $132.00
8/7/2026	ALKS Alkermes	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
8/7/2026	AGIO Agios Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$31.00 ➝ $34.00

(Data available from 9/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGIO Agios Pharmaceuticals	$54.03M	37.13	N/A	N/A	$20.46 per share	1.64
ALKS Alkermes	$1.48B	5.23	$1.67 per share	27.46	$11.02 per share	4.17
RYTM Rhythm Pharmaceuticals	$189.76M	37.82	N/A	N/A	$2.08 per share	50.34
SYRE Spyre Therapeutics	$890K	8,952.09	N/A	N/A	$7.21 per share	12.57

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGIO Agios Pharmaceuticals	-$412.78M	-$7.01	N/A	N/A	N/A	-418.24%	-35.67%	-33.06%	10/29/2026 (Estimated)
ALKS Alkermes	$241.66M	$0.38	120.98	191.54	N/A	3.96%	4.15%	2.19%	10/28/2026 (Estimated)
RYTM Rhythm Pharmaceuticals	-$196.54M	-$3.11	N/A	N/A	N/A	-85.59%	-159.87%	-44.00%	11/3/2026 (Estimated)
SYRE Spyre Therapeutics	-$155.20M	-$1.95	N/A	N/A	N/A	N/A	-30.74%	-22.23%	11/3/2026 (Estimated)

Latest AGIO, SYRE, ALKS, and RYTM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/4/2026	Q2 2026	RYTM Rhythm Pharmaceuticals	-$0.8072	-$0.73	+$0.0772	-$0.73	$67.66 million	$71.26 million
8/4/2026	Q2 2026	SYRE Spyre Therapeutics	-$0.7589	-$0.36	+$0.3989	-$0.36	N/A	N/A
7/30/2026	Q2 2026	AGIO Agios Pharmaceuticals	-$1.65	-$1.69	-$0.04	-$1.69	$26.40 million	$44.75 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ALKS Alkermes	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGIO Agios Pharmaceuticals	N/A	10.22	9.79
ALKS Alkermes	0.82	2.30	1.85
RYTM Rhythm Pharmaceuticals	N/A	3.45	3.20
SYRE Spyre Therapeutics	N/A	18.53	18.53

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGIO Agios Pharmaceuticals	N/A
ALKS Alkermes	95.21%
RYTM Rhythm Pharmaceuticals	N/A
SYRE Spyre Therapeutics	80.39%

Insider Ownership

Company	Insider Ownership
AGIO Agios Pharmaceuticals	5.40%
ALKS Alkermes	4.59%
RYTM Rhythm Pharmaceuticals	5.90%
SYRE Spyre Therapeutics	15.69%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGIO Agios Pharmaceuticals	540	59.70 million	56.48 million	Optionable
ALKS Alkermes	2,050	167.76 million	160.06 million	Optionable
RYTM Rhythm Pharmaceuticals	414	68.53 million	64.49 million	Optionable
SYRE Spyre Therapeutics	112	87.94 million	74.14 million	Optionable

AGIO, SYRE, ALKS, and RYTM Headlines

Recent News About These Companies

Engineers Gate Manager LP Takes $3.42 Million Position in Spyre Therapeutics, Inc. $SYRE

2 hours ago | marketbeat.com

11,250 Shares in Spyre Therapeutics, Inc. $SYRE Acquired by VIRGINIA RETIREMENT SYSTEMS ET Al

2 hours ago | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Earns Outperform Rating from Wedbush

September 11 at 2:26 AM | americanbankingnews.com

Spyre Therapeutics (SYRE) Reports SPY003 Endoscopic Improvement. Can Randomized Testing Confirm It?

September 10, 2026 | insidermonkey.com

Squarepoint Ops LLC Invests $12.39 Million in Spyre Therapeutics, Inc. $SYRE

September 10, 2026 | marketbeat.com

Allianz Asset Management GmbH Takes Position in Spyre Therapeutics, Inc. $SYRE

September 10, 2026 | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Earns Buy Rating from BTIG Research

September 10, 2026 | americanbankingnews.com

Spyre Therapeutics, Inc. (SYRE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

September 9, 2026 | seekingalpha.com

Spyre Therapeutics (SYRE) Stock Surges as Guggenheim Declares It Top Biotech Following UC Trial Results

September 9, 2026 | blockonomi.com

Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study

September 9, 2026 | zacks.com

Wedbush Reiterates "Outperform" Rating for Spyre Therapeutics (NASDAQ:SYRE)

September 9, 2026 | marketbeat.com

Maven Securities LTD Invests $3.55 Million in Spyre Therapeutics, Inc. $SYRE

September 9, 2026 | marketbeat.com

Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD ...

September 8, 2026 | markets.businessinsider.com

Spyre Therapeutics Reports Positive Phase 2 SPY003 Data In Ulcerative Colitis

September 8, 2026 | rttnews.com

Spyre Therapeutics' SPY003 Meets Phase 2 Primary Endpoint in Ulcerative Colitis

September 8, 2026 | finance.yahoo.com

Spyre Therapeutics' (SYRE) Buy Rating Reiterated at BTIG Research

September 8, 2026 | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Down - Here's What Happened

September 8, 2026 | marketbeat.com

Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations

September 8, 2026 | globenewswire.com

Spyre Therapeutics Announces Grants of Inducement Awards

September 4, 2026 | globenewswire.com

Spyre Therapeutics (NASDAQ:SYRE) Insider Heidy King-Jones Sells 400 Shares of Stock

September 4, 2026 | insidertrades.com

Insider Selling: Spyre Therapeutics (NASDAQ:SYRE) Insider Sells $36,000.00 in Stock

September 3, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AGIO, SYRE, ALKS, and RYTM Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

$33.60 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$33.00 -0.60 (-1.79%)

As of 09/11/2026 07:30 PM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Alkermes NASDAQ:ALKS

$45.97 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$45.68 -0.29 (-0.63%)

As of 06:23 AM Eastern

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Rhythm Pharmaceuticals NASDAQ:RYTM

$104.71 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$104.35 -0.36 (-0.34%)

As of 06:06 AM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Spyre Therapeutics NASDAQ:SYRE

$90.60 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$90.50 -0.10 (-0.11%)

As of 05:39 AM Eastern

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AGIO, SYRE, ALKS, and RYTM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AGIO, SYRE, ALKS, and RYTM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AGIO, SYRE, ALKS, and RYTM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AGIO, SYRE, ALKS, and RYTM Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

Alkermes NASDAQ:ALKS

Rhythm Pharmaceuticals NASDAQ:RYTM

Spyre Therapeutics NASDAQ:SYRE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AGIO, SYRE, ALKS, and RYTM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AGIO, SYRE, ALKS, and RYTM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AGIO, SYRE, ALKS, and RYTM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AGIO, SYRE, ALKS, and RYTM Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

Alkermes NASDAQ:ALKS

Rhythm Pharmaceuticals NASDAQ:RYTM

Spyre Therapeutics NASDAQ:SYRE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools